Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUSTAIRE vs ALBUTEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm,Off-label: Acute hyperkalemia (via nebulization)
50 mg orally twice daily
2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Terminal elimination half-life is 3.8-6.0 hours. In patients with asthma, the half-life is similar, but clinical effect duration is shorter due to rapid redistribution from the receptor site.
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Primarily metabolized via sulfotransferase (SULT1A3) to inactive sulfate conjugate; minor hepatic metabolism by CYP450 enzymes.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Primarily renal: approximately 60-70% of the dose is excreted in urine as unchanged drug and metabolites (sulfate conjugate) within 24 hours. Fecal excretion accounts for less than 10%.
Approximately 95% bound to albumin.
Approximately 52-65% bound to human serum albumin and alpha-1-acid glycoprotein.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
Approximately 1.4-2.0 L/kg. This relatively large Vd indicates extensive distribution into tissues, including lung parenchyma.
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
Inhaled: 10-20% of the dose reaches the lungs systemically; Oral: approximately 28-40% (due to first-pass metabolism to sulfate conjugate); Subcutaneous: nearly 100%.
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
No dosage adjustment required for renal impairment.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
Nebulized: 0.05-0.15 mg/kg/dose (minimum 1.25 mg) every 4-6 hours as needed. MDI: 1-2 inhalations (90 mcg/inhalation) every 4-6 hours as needed. Maximum: 12 inhalations/day.
Age >65 years: initiate at 25 mg twice daily; monitor renal function
Initiate at lower end of dosing range; monitor for tremors, tachycardia, and hypertension. No specific dose adjustment required.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
None.
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: increased heart rate, hypertension, arrhythmias,Hypokalemia may occur with high doses,Immediate hypersensitivity reactions possible,Use caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
Hypersensitivity to albuterol or any component of the formulation
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
No clinically significant food interactions. Caffeine may potentiate stimulant effects; avoid excessive caffeine intake.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperglycemia; fetal tachycardia, hypoglycemia at birth if used near term. Possible association with gastroschisis in first trimester from some studies, but not confirmed.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
Excreted into breast milk in low concentrations; M/P ratio not established. Limited data suggest no adverse effects in infants. American Academy of Pediatrics considers compatible with breastfeeding. Use with caution in preterm infants or those with tachycardia.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
No specific dose adjustment required for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, but clinical significance is minimal. Use lowest effective dose to control symptoms.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
Monitor for paradoxical bronchospasm; use with caution in patients with cardiovascular disorders due to beta-adrenergic stimulation; may cause hypokalemia with high doses; combine with ipratropium for acute exacerbations; not recommended for long-term control without anti-inflammatory therapy.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
Use only as prescribed; do not exceed recommended dose.,Rinse mouth after use to prevent oral candidiasis (if using with corticosteroid), but albuterol alone does not require rinsing.,Seek emergency care if symptoms worsen or inhaler provides less relief.,Shake inhaler well before each use; use spacer if available for better delivery.,Monitor for palpitations, tremors, or nervousness; report if severe.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUSTAIRE vs ALBUTEROL, answered by our medical review team.
SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. ALBUTEROL is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUSTAIRE and ALBUTEROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. The standard adult dose of ALBUTEROL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUSTAIRE and ALBUTEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . ALBUTEROL is classified as Category C. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.